Afon Technology Limited’s (“Afon Technology”) board appoints Hyman Capital as advisor to its fund raising activities
The Board of Afon Technology has pleasure in announcing it is approaching the private funding market to raise £ 4 m to fund further miniaturisation of their medical device and manufacturing. The board has selected Hyman Capital to advise on this process.
Afon Technology has the single focus of commercialising a wearable, non-invasive blood glucose monitor to benefit people with diabetes the world over. Based on proven and patented technology, they have created a non-invasive, real-time and continuous glucose sensor that will empower people with diabetes in self-management and provide their clinicians with a history of their blood glucose variations. The compact device is designed to be worn with a watchstrap and connected via Bluetooth to the user’s smart watch/device. The device created gives individuals’ freedom from the constraints of conventional finger-stick devices.
Afon Technology is excited to report that they have appointed Hyman Capital as advisor to its fund-raising activities. Afon Technology is working with Hyman Capital, to identify potential investors to raise the £ 4 million.
Sabih Chaudhry, CEO of Afon Technology said, “We selected Hyman Capital because of their network of connections with appropriate investors and their understanding, experience and empathy for our company and development.”
Clive Hyman said, “We are glad to be working with Afon Technology, we have taken the time to understand the business and are working hand in glove with the management team to hone their materials.”
Enquiries welcomed
Clive Hyman, Hyman Capital +44 (0) 7388 245 446
Sabih Chaudhry, Afon Technology +44 (0) 7880 548 838